BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

INCB18424: SPA received

Incyte received an SPA from FDA for the planned open-label, international Phase III RESPONSE trial to evaluate oral INCB18424 vs. best available therapy in about 300 patients with PV who are resistant to or intolerant of hydroxyurea. Patients receiving best available therapy who fail to meet the primary...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >